Hepatitis B Vaccination Guidelines

Introduction to Hepatitis B Vaccination

The Centers for Disease Control and Prevention recommends that individuals who received the complete hepatitis B vaccine series as infants and initially responded to it do not need a booster dose, as protection persists for 30 years or more even when antibody levels decline 1

Immunologic memory persists despite declining antibody levels, with 88% of individuals who received the complete 3-dose series as children or adults developing an anamnestic response when given a challenge dose 30 years later, indicating persistent immunity to HBV infection 1
Protection against chronic infection continues, with data suggesting protection against acute symptomatic and chronic HBV infection persists for 30 years or more among immunocompetent individuals who originally responded to the vaccine, even when anti-HBs levels fall below the protective threshold 1
Antibody decline is expected and normal, with approximately 16% of individuals vaccinated at age <1 year having antibody levels ≥10 mIU/mL 18 years following vaccination, compared with 74% for those vaccinated at age ≥1 year, but this decline does not indicate loss of protection 1

The American College of Physicians and other medical organizations recommend that healthcare workers who were vaccinated as infants should have their anti-HBs level measured upon hire or matriculation, and if <10 mIU/mL, they should receive one additional dose followed by retesting 1-2 months later 2
Hemodialysis patients require annual anti-HBs testing and booster doses when levels fall below 10 mIU/mL, according to the National Kidney Foundation and other organizations 2, 3
Immunocompromised individuals, including HIV-infected persons, may require more frequent monitoring and booster doses, as recommended by the Infectious Diseases Society of America 2
Sexual partners or household contacts of HBsAg-positive individuals should be tested and revaccinated if anti-HBs <10 mIU/mL, as recommended by the Centers for Disease Control and Prevention 2

Unvaccinated or incompletely vaccinated individuals of any age should receive the complete 3-dose series, according to the Centers for Disease Control and Prevention and the American Academy of Pediatrics 4, 3
Children and adolescents aged <19 years who were not vaccinated as infants should receive catch-up vaccination at any age, as recommended by the American Academy of Pediatrics and the Centers for Disease Control and Prevention 4

The Centers for Disease Control and Prevention recommends that children with immunodeficiency require serologic monitoring and booster doses based on antibody levels, as they may lose protective immunity over time 5
HIV-infected children should receive postvaccination serologic testing after completing the primary series and may require periodic monitoring with booster doses if anti-HBs falls below 10 mIU/mL 5
Other immunocompromised children, including hematopoietic stem-cell transplant recipients or those receiving chemotherapy, should undergo postvaccination serologic testing and receive boosters based on antibody monitoring 5

The Centers for Disease Control and Prevention recommends that children on hemodialysis or predialysis require annual anti-HBs testing and should receive booster doses when levels fall below 10 mIU/mL, including peritoneal dialysis and home dialysis patients 5

The Advisory Committee on Immunization Practices guidelines do not specifically mandate routine booster doses for immunocompetent children with chronic liver disease, but consider serologic testing and booster vaccination if anti-HBs levels are found to be <10 mIU/mL 6

The Centers for Disease Control and Prevention recommends that children born to HBsAg-positive mothers require postvaccination serologic testing at 9-12 months after completing the vaccine series, and if anti-HBs is <10 mIU/mL, revaccinate with a single dose and retest 1-2 months later 6
If anti-HBs remains <10 mIU/mL after single-dose revaccination, administer two additional doses followed by serologic testing 1-2 months after the final dose 5
Alternatively, these children may receive a complete second 3-dose series followed by postvaccination testing 1-2 months after the final dose 5